AstraZeneca said that a stroke of good fortune that resulted from a dosing error was behind trial data presented on Monday that will allow it and Oxford University to make their case with regulators for a COVID-19 vaccine with up to 90% efficacy.
AstraZeneca on Monday said the vaccine could be around 90% effective, when administered as a half dose followed by a full dose a month later, citing data from late-stage trials in Britain and Brazil.
